Safety, tolerability and pharmacokinetics of the histamine H₃ receptor antagonist, <scp>ABT</scp>‐288, in healthy young adults and elderly volunteers

Abstract

Based on the above results, 1 and 3 mg once-daily doses of ABT-288 were advanced to phase 2 evaluation in Alzheimer's patients.